Prosecution Insights
Last updated: November 08, 2026
Application No. 18/192,398

METHOD OF TREATING GRAFT VERSUS HOT DISEASE

Final Rejection §112§DP
Filed
Mar 29, 2023
Priority
Jul 02, 2010 — provisional 61/398,950 +5 more
Examiner
FOX, ALLISON M
Art Unit
1633
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Mesoblast Inc.
OA Round
2 (Final)
71%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allowance Rate
480 granted / 676 resolved
+11.0% vs TC avg
Strong +36% interview lift
Without
With
+35.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
37 currently pending
Career history
710
Total Applications
across all art units

Statute-Specific Performance

§101
7.1%
-32.9% vs TC avg
§103
28.8%
-11.2% vs TC avg
§102
16.4%
-23.6% vs TC avg
§112
27.5%
-12.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 676 resolved cases

Office Action

§112 §DP
DETAILED ACTION The present application is being examined under the pre-AIA first to invent provisions. Applicants’ response of 8/21/2026 has been received and entered into the application file. Claims 2-10 and 12-16 are pending, all of which have been considered on the merits. Claim Interpretation The following facts are set forth to clearly describe the state of the art and terminology used: STRO-1 is a marker of a subset of primitive multipotent stromal cells (synonymous with mesenchymal stromal cells, mesenchymal stem cells, and multipotent stem cells) (MSCs). STRO-1 is also expressed on a number of non-multipotent cells (i.e. erythrocytes). STRO-1+ cells include STRO-1Bright, STRO-1Intermediate, and STRO-1dim cells. STRO-1Bright cells defines a subset of MSCs. Thus all STRO-1Bright cells are MSCs, however, not all MSCs are STRO-1Bright. Not all MSCs are even STRO-1+ (MSCs can be STRO-1-, based on statement of instant specification at Pg. 7, ln 19-21). The term “mesenchymal precursor cell (MPC)” is not explicitly defined in the instant specification or in the art. However, the term is used in related works (Gronthos et al (WO 06/032092); Simmons et al (WO 01/04268)) to refer to STRO-1Bright cells present in bone marrow/freshly harvested bone marrow. These MPCs are STRO-1Bright and, inter alia, ALP+. The MPCs are distinguished from their culture expanded progeny (multipotent expanded mesenchymal precursor cells (MEMPS)), which are also STRO-1Bright but are ALP-. For interpretation of the instant claims, “MPCs” is interpreted only as meaning the cell must be a precursor of mesenchymal cell, it is interpreted as synonymous with MSC. TNAP is synonymous with STRO-3. STRO-1+/TNAP+ cells are a subset of STRO-1Bright MSCs. Thus STRO-1+/TNAP+ cells are actually STRO-1Bright/TNAP+. Claim 2 is understood to be directed to a method for treating GvHD complications in a human patient, wherein the method comprises administering to the human patient a therapeutically effective amount of (1) cells enriched for STRO-1+/TNAP+ mesenchymal precursor cells (MPCs), or (2) multipotential cells culture-expanded from STRO-1+/TNAP+ MPCs, wherein the cells of (1) or (2) are CD34-. It is first necessary to define the patient populations covered by the instant claims: The patient must be human. Patients in need of treatment of GvHD complications are limited to those who are currently experiencing GvHD complications. The specific complication is not defined, and thus any GvHD complication is included. However, one must still have GvHD to be included within this patient population. Second, it is necessary to define what is being administered to the patients: For (1) cells enriched for STRO-1+/TNAP+ MPCs, wherein the cells are CD34- : As discussed above, STRO-1+/TNAP+ MPCs are interpreted as referring to a subset of STRO-1Bright/TNAP+ MSCs. The term enriched is interpreted as meaning a population which has been treated so as to increase the proportion of a specific cell type therein (in the instant case STRO-1+/TNAP+ MPCs) compared to an untreated population. Whole bone marrow will not read on the administered composition because it is not enriched for STRO-1+/TNAP+ MPCs (also because whole bone marrow contains CD34+ cells). The mononuclear fraction of bone marrow will not read on the administered composition because it is not enriched for STRO-1+/TNAP+ MPCs (also because it contains CD34+ cells). A population of multipotent stromal cells isolated from the bone marrow will not meet the claim limitation because it is not enriched for STRO-1+/TNAP+ MPCs (note also a population of multipotent stromal cells can be completely STRO-1-). For (2) multipotential cells culture-expanded from STRO-1+/TNAP+ MPCs, wherein the cells are CD34- : A “culture-expanded population of STRO-1+/TNAP+ MPCs” means that the STRO-1+/TNAP+ MPCs have been expanded in culture. Gronthos et al (WO 06/032092) has shown that when STRO-1Bright MPCs are expanded in culture, they change phenotype (i.e. they lose, at least, ALP expression). The MEMPs of Gronthos et al read on multipotential cells culture-expanded from STRO-1+/TNAP+ MPCs. There is no evidence that shows that STRO-1+ cells can give rise to STRO-1- MSCs; thus there is no evidence that STRO-1+/TNAP+ MPCs can give rise to STRO-1- MSCs. Thus, STRO-1- MSCs are not within the scope of the instant claims. STRO-1+/TNAP+ MPCs can eventually give rise to terminally differentiated cells, such as adipocytes, chondrocytes and osteocytes, but these are not within the scope of the current claims because the claim limits to multipotential cells culture-expanded from STRO-1+/TNAP+ MPCs. Terminally differentiated cells are not multipotential cells. Claim 6 is being interpreted as meaning the STRO-1+, TNAP+ cells are allogenic to the human being treated. Status of Prior Rejections/Response to Arguments RE: Objection to claim 1: The amendment to claim 1 is effective to obviate the previous basis of objection. RE: Duplicate Claim Warning: Cancellation of claim 1 renders the warning moot. RE: Rejection of claims 1-16 under pre-AIA 35 USC 112, first paragraph, lack of enablement for full scope: The amendment to independent claim 2 is effective to limit the claims to a scope which is fully enabled. The rejection is withdrawn. RE: Rejection of claims 1-16 under pre-AIA 35 USC 112, second paragraph: The amendments to the claims are effective to overcome the previous basis of rejections, but a new rejection is necessitated over claims 3-5. . RE: Rejection of claims 1, 2, and 14 under 35 USC pre-AIA 35 USC 102(b) over Gronthos et al: The amendment to claim 2 to limit the method to treatment of humans who are suffering from complications of GvHD is sufficient to differentiate from Gronthos et al. Gronthos et al does not teach treating GvHD. The rejection is withdrawn. RE: Rejection of claims 1, 2, and 6-14 under 35 USC pre-AIA 35 USC 103(a) over Gronthos et al: The amendment to claim 2 to limit the method to treatment of humans who are suffering from complications of GvHD is sufficient to differentiate from Gronthos et al. Gronthos et al does not teach treating GvHD. The rejection is withdrawn. RE: Rejection of claims 1-16 on grounds of non-statutory double patenting over claims of US Patent Nos 9301978, 10849932, 8828372 and 9415072: Applicants requested the rejections be held in abeyance until indication of allowable subject matter. Though Applicants did not list 10105394, it is presumed the response is applicable to that patent, as well. The rejection over US Patent 9415072 is withdrawn, as the patented claims do not cover treatment of GvHD. The remaining rejections are modified to address the current claim limitations. Claim Objection Claim 2 is objected to for a minor informality: In line 7 the word “patient’s” is mis-spelled [sic: pateient’s]. Correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 3 and 5 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Regarding claims 3 and 5: Claim 3 states the therapeutically effective amount of cell populations (1) or (2) are administered to the human patient prior to administration of precursors of bone marrow lineage cells. The claims are considered indefinite because it is not clear if the method is requiring an active step of administering precursors of bone marrow lineage cells. If applicants intend for the method to require an active step of administering precursors of bone marrow lineage cells, then at least claim 3 should be amended to “…wherein the method further comprises administering precursors of bone marrow lineage cells, wherein the therapeutically effective amount of the population of (1)…. or (2)… is administered to the human patient prior to administration of the precursors of bone marrow lineage cells.” Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP §§ 706.02(l)(1) - 706.02(l)(3) for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. Claims 2-10 and 12-16 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 2-15 of U.S. Patent No. 9,301,978. Although the claims at issue are not identical, they are not patentably distinct from each other because the patented claims anticipate the instant claims. Regarding instant claim 2: Patented claim 15 anticipates instant claim 2 for the embodiment wherein the administered cells are (2) multipotential cells culture expanded from STRO-1+, TNAP+ MPCs. Patented claim 15 recites administration of cells culture expanded from STRO-1bright cells. Both the patent and the current claim cover administration of “MEMPs”. Regarding instant claim 3 and 5: In so far as claims 3 and 5 are interpreted as requiring administration of precursors of bone marrow lineage cells, patented claim 15, as it depends from claim 2, teaches this limitation. Regarding claim 4: Following the discussion of claim 3 above, the timing of the administration of the precursors of bone marrow lineage cells would have been prima facie obvious, absent evidence of criticality associated with timing. Regarding claim 6: The combination of patented claims 2, 15 and 4 render obvious all limitations of instant claim 6. Regarding claims 7-8: The combination of patented claims 2, 15 and 6 render obvious all limitations of instant claims 7-8. Regarding claims 9, 10, 12 and 13: The combination of patented claims 2, 15 and 10 render obvious all limitations of instant claims 9, 10, 12 and 13. Regarding claim 14: The combination of patented claims 2, 15 and 11 render obvious all limitations of instant claim 14. Regarding claim 15: The combination of patented claims 2, 15 and 12 render obvious all limitations of instant claim 15. Regarding claim 16: The combination of patented claims 2, 15 and 13 render obvious all limitations of instant claim 16. Claims 2-10 and 12-16 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-13 of U.S. Patent No. 10105394. Although the claims at issue are not identical, they are not patentably distinct from each other because the patented claims anticipate the instant claims. Regarding claim 2: Patented claim 1 anticipates instant claim 2 for the embodiment wherein the administered cells are (2) multipotential cells culture expanded from STRO-1+, TNAP+ MPCs. Patented claim 1 recites method of treating GvHD in a human patient by administrating cells culture expanded from STRO-1bright cells. Both the patent and the current claim cover administration of “MEMPs”. Regarding claim 4: In the embodiment of patented claim 1 where the subject is undergoing bone marrow or hematopoietic stem cell transplantation, the patient is also being co-administered precursors of bone marrow lineage cells, thereby anticipating instant claim 4. Regarding claims 3 and 5: In the embodiment of patented claim 1 where the subject is about to undergo bone marrow or hematopoietic stem cell transplantation, it would have been prima facie obvious to have further administered the bone marrow or hematopoietic stem cells to the patient following the patented method. This conclusion of obviousness is based on a clear suggestion in the prior art that the method is intended to precede bone marrow or hematopoietic stem cell transplantation. Thus patented claim 1 renders obvious instant claims 3 Regarding claims 5, 6 and 15: Following the discussion of claim 3 above, patented claim 4 further teaches the administered cells are allogenic, and patented claim 12 teaches the administration can be to a human suffering from aplastic anemia, which is a malignant disease. Regarding claims 7: Following the discussion of claim 3 above, patented claim 5 anticipates instant claim 7. Regarding claim 8: Following the discussion of claim 3 above, patented claim 6 anticipates instant claim 8. Regarding claims 9, 10, 12 and 13: Following the discussion of claim 3 above, patented claims 7-10 anticipate instant claims 9, 10, 12 and 13. Regarding claim 14: Following the discussion of claim 3 above, patented claim 11 anticipates instant claim 14. Regarding claim 16: Following the discussion of claim 3 above, patented claim 13 anticipates instant claim 16. Claims 2-10 and 12-16 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-13 of U.S. Patent No. 10849932. Although the claims at issue are not identical, they are not patentably distinct from each other because the patented claims anticipate and/or render obvious the instant claims. Regarding claim 2: Patented claim 1 anticipates claim 2. Regarding claim 4: In the embodiment of patented claim 1 where the subject is undergoing bone marrow or hematopoietic stem cell transplantation, the patient is also being co-administered precursors of bone marrow lineage cells, thereby anticipating instant claim 4. Regarding claims 3 and 5: In the embodiment of patented claim 1 where the subject is about to undergo bone marrow or hematopoietic stem cell transplantation, it would have been prima facie obvious to have further administered the bone marrow or hematopoietic stem cells to the patient following the patented method. This conclusion of obviousness is based on a clear suggestion in the prior art that the method is intended to precede bone marrow or hematopoietic stem cell transplantation. Thus patented claim 1 renders obvious instant claim 3 Regarding claim 6: Patented claim 4 anticipates claim 6. Regarding claims 7 and 8: Patented claim 6 anticipates claims 7-8. Regarding claim 9, 10, 12 and 13: Patented claim 10 anticipates claims 9, 10, 12 and 13. Regarding claim 14: Patented claim 11 anticipates claim 14. Regarding claim 15: Patented claim 12 anticipates claim 15. Regarding claim 16: Patented claim 13 anticipates claim 16. Claims 2, 4-6 and 15 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 2 and 15 of U.S. Patent No. 8,828,375. Although the claims at issue are not identical, they are not patentably distinct from each other because the patented claims render obvious the instant claims. Specifically patented claim 1 recites a method of transplanting hematopoietic precursor cells into a subject in need thereof, wherein the hematopoietic precursor cells have been previously expanded in vitro in the presence of STRO-1bright cells. Regarding instant claims 2, 3 and 4: Patented claim 1 recites administering the hematopoietic cells which have been expanded in the presence of STRO-1bright cells. Because the STRO-1bright cells are cultured, they will necessarily give rise to some progenitors during the culture stage, these progeny read will include MEMPs reading on current cell population (2) of current claim 2. While the patented claim does not specify that the STRO-1bright cells and their progeny are administered along with the expanded hematopoietic cells, the claim does not require a step of separation or isolation of the hematopoietic cells, and it is thus considered at least prima facie obvious to have administered the entire cell culture. The STRO-1bright cell progeny read on '(2) multipotential cells culture expanded from STRO-1bright cells” and the hematopoietic precursor cells read on ‘precursors of bone marrow lineage cells'. Administration of the complete expanded culture would involve co-administration of the two cell types. The method is inherently effective to treat complications of GvHD, given that the same cells are administered to the same patient population as required by the instant claims. Regarding claims 5 and 15: Patented claim 15 defines the subject as one having various malignant blood disorders, including aplastic anemia. Regarding claim 6: Patented claim 2 defines the population of cells enriched for STRO-1bright as being allogeneic. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ALLISON M FOX whose telephone number is (571)272-2936. The examiner can normally be reached M-F 10-6 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Christopher Babic can be reached on 571-272-8507. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ALLISON M FOX/Primary Examiner, Art Unit 1633
Read full office action

Prosecution Timeline

Mar 29, 2023
Application Filed
Jun 03, 2026
Non-Final Rejection mailed — §112, §DP
Aug 21, 2026
Response Filed
Sep 24, 2026
Final Rejection mailed — §112, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12773428
PRIMED MUSCLE PROGENITOR CELLS AND USES THEREOF
4y 10m to grant Granted Oct 27, 2026
Patent 12773467
METHOD FOR PRODUCING COLLAGEN HYDROGELS
4y 4m to grant Granted Oct 27, 2026
Patent 12753392
Neo-Islets Comprising Stem and Islet Cells and Treatment of Diabetes Mellitus Therewith
4y 0m to grant Granted Oct 06, 2026
Patent 12686880
METHODS FOR INCREASING MANNOSE CONTENT OF RECOMBINANT PROTEINS
4y 3m to grant Granted Jul 21, 2026
Patent 12680065
Artificial Placenta And Methods Of Preparation
4y 6m to grant Granted Jul 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
71%
Grant Probability
99%
With Interview (+35.7%)
3y 3m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 676 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month